Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
Completed
Hoffmann-La Roche
Phase 2
1969-12-31
PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir
mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC)
vs. Ro 31-8959 plus AZT plus ddC.
SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of
the three regimens.
A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
Completed
Stanford University
Phase 1
1969-12-31
To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected
patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine
Completed
Hoffmann-La Roche
Phase 2
1969-12-31
To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone,
zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing
or unable to take zidovudine (AZT).
A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment
Completed
Hoffmann-La Roche
Phase 3
1969-12-31
To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of
saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro
31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different
regimens.
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
Completed
AIDS Associated Malignancies Clinical Trials Consortium
Phase 2
1997-06-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with
AIDS-related Kaposi's sarcoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
